Palbociclib in combination with letrozole as first‐line treatment for advanced breast cancer: A Japanese phase II study

This single‐arm, open‐label, phase II study in 42 Japanese postmenopausal patients with estrogen receptor‐positive/human epidermal growth factor receptor 2‐negative (ER+/HER2−) advanced breast cancer evaluated the efficacy, safety, and pharmacokinetics of first‐line palbociclib (125 mg once daily, 3 weeks on/1 week off) coadministered with letrozole (2.5 mg once daily). Primary endpoint of investigator‐assessed 1‐year progression‐free survival (PFS) probability was 75.0% (90% CI, 61.3%‐84.4%), far surpassing the 40% lower limit of the 90% CI supporting efficacy. Median duration of treatment was 438 days. Among secondary efficacy measures, median PFS was not reached (95% CI, 16.7: not estimable), 17/42 patients (40.5%) had an objective response, 36/42 (85.7%) maintained disease control, and 27/42 (64.3%) remained in follow‐up. Median overall survival was not reached, and 1‐year survival probability was 92.9% (95% CI, 79.5%‐97.6%). Results of intensive pharmacokinetics in a subset of 6 patients showed palbociclib steady‐state mean area under the plasma concentration‐time curve over the dosing interval [τ] and mean maximum plasma concentration were 1979 ng·h/mL and 124.7 ng/mL, respectively. For day 15 plasma samples from cycles 1 and 2, geometric mean of the within‐patient mean trough concentration was 90.1 ng/mL. The most common treatment‐related adverse events were neutropenia (100%) and stomatitis (73.8%). There was 1 case of treatment‐related febrile neutropenia. Toxicities were generally tolerated and manageable by dose modifications and/or medical care. Efficacy and safety of first‐line palbociclib plus letrozole therapy is supported in Japanese postmenopausal patients with treatment‐naive ER+/HER2− advanced breast cancer.

[1]  H. Hunger,et al.  EDITION , 2018, Moshe Bar Kepha's Commentary on the Gospel of Luke.

[2]  K. Gelmon,et al.  291PPALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor−positive (ER+)/human epidermal growth factor receptor 2−negative (HER2–) first-line advanced breast cancer (ABC) receiving palbociclib + letrozole (P+L) , 2017 .

[3]  K. Gelmon,et al.  Palbociclib (PAL) + letrozole (L) as first-line (1L) therapy (tx) in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Efficacy and safety across patient (pt) subgroups. , 2017 .

[4]  H. Iwata,et al.  PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients , 2017, Journal of global oncology.

[5]  Y. Kamatani,et al.  Characteristics and prognosis of Japanese female breast cancer patients: The BioBank Japan project , 2017, Journal of epidemiology.

[6]  A. Awada,et al.  Advances in chemical pharmacotherapy to manage advanced breast cancer , 2017, Expert opinion on pharmacotherapy.

[7]  K. Gelmon,et al.  Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.

[8]  K. Gelmon,et al.  Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC) , 2016 .

[9]  D. Jayne,et al.  SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .

[10]  M. Kodaira,et al.  Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients , 2016, Cancer science.

[11]  F. Hara,et al.  The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition , 2016, Breast Cancer.

[12]  M. Nakano,et al.  Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective Study , 2015, PloS one.

[13]  Hiroshi Nishimoto,et al.  An updated report on the trends in cancer incidence and mortality in Japan, 1958-2013. , 2015, Japanese journal of clinical oncology.

[14]  D. Heitjan,et al.  CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment , 2014, Clinical Cancer Research.

[15]  A. Milani,et al.  Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions. , 2014, World journal of clinical oncology.

[16]  R. Chlebowski Changing concepts of hormone receptor-positive advanced breast cancer therapy. , 2013, Clinical breast cancer.

[17]  H. Iwata,et al.  A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer , 2013, Breast Cancer Research and Treatment.

[18]  F. Zeman,et al.  Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry , 2013, Breast Cancer Research and Treatment.

[19]  K. Katanoda,et al.  An updated report of the trends in cancer incidence and mortality in Japan. , 2013, Japanese journal of clinical oncology.

[20]  K. Flaherty,et al.  Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer , 2011, Clinical Cancer Research.

[21]  J. Dering,et al.  PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.

[22]  D. W. Fry,et al.  Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. , 2005, Journal of medicinal chemistry.

[23]  N. Pryer,et al.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.

[24]  Xin Huang,et al.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.

[25]  F. Hara,et al.  The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer , 2014, Breast Cancer.

[26]  L. Fallowfield,et al.  Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.